#USA #New York #Class Action #Levi & Korsinsky #aTyr Pharma

Class Action Alert: aTyr Pharma Investors Urged to Join Lawsuit Before December 2025 Deadline

aTyr Pharma, Inc. Class Action Overview

Levi & Korsinsky, LLP has issued a notice regarding a class action securities lawsuit against aTyr Pharma, Inc. (NASDAQ: ATYR). Investors who suffered losses during the fraudulent activities occurring between November 7, 2024, and September 12, 2025, are invited to participate in the class action before the deadline of December 8, 2025, to request appointment as a lead plaintiff.

Background Information on the Case

The lawsuit implicates aTyr Pharma, a biotechnology company, for allegedly engaging in securities fraud. According to the complaint filed by Levi & Korsinsky, the defendants made false and misleading claims about the efficacy of their leading drug, Efzofitimod. Specifically, they touted the drug's ability to allow patients to completely taper off steroid usage while concealing material adverse facts regarding its true effectiveness.

The gravity of the situation became apparent on September 15, 2025, during an investor call where aTyr announced the EFZO-FIT study did not meet its primary objective. This announcement directly contradicted earlier assertions made by the company, revealing that the drug did not achieve the expected change in mean daily oral corticosteroid (OSC) doses by week 48. This revelation caused a significant decline in aTyr’s stock price, dropping from $6.03 per share on September 12, 2025, to merely $1.02 per share by September 15, marking an alarming decrease of 83.2% within a single trading day.

Implications for Investors

Investors who purchased aTyr securities during the outlined timeframe may be eligible for compensation stemming from the losses they incurred due to the company’s alleged misrepresentation. The firm encourages individuals who believe they are part of the class to contact them for more information on how to participate.

No Financial Burden to Plaintiffs

It is crucial for investors to understand that should they choose to join the lawsuit, they will not incur any out-of-pocket costs related to the litigation. Levi & Korsinsky has committed to a no-cost participation policy, making it accessible for all investors affected by the alleged fraud. Furthermore, participating in this class action does not require appointment as a lead plaintiff; simply being part of the class will suffice to potentially receive a portion of any recovery.

Why Choose Levi & Korsinsky?

Levi & Korsinsky has established a robust history over the past two decades, successfully advocating for investors’ rights and obtaining hundreds of millions of dollars in settlements. With a dedicated team of over 70 professionals specializing in complex securities litigation, the firm has consistently earned high rankings in securities class action services. Their diligence and experience position investors in a favorable light when pursuing justice in cases of securities fraud.

How to Contact and Proceed

Investors affected by the alleged securities fraud can visit the firm’s website for a fulsome submission form or directly contact Joseph E. Levi, Esq. via email or phone. Investors are urged to act promptly given the approaching December 8, 2025, cutoff for joining as lead plaintiffs.

For further information, individuals may also access the link provided below that leads to a detailed class action submission form: aTyr Pharma Class Action Submission Form.

In conclusion, the impending lawsuit against aTyr Pharma Inc. exemplifies the critical role that investors play in holding companies accountable for their disclosures and misleading statements. If you have suffered financial loss during this period, it is essential to engage with legal representation without delay.